TreatSMA

TreatSMA sponsor Rare Disease Day event – 26 February 2020

TreatSMA are proud to announce that we will be one of the sponsors for Royal Holloway’s 10th Annual Rare Disease Day Event on Wednesday 26th of February.

This is a massive event with an impressive programme, and list of participants taking part on the day.

We ourselves will have a stall, and we welcome you all to come down and support us and other rare diseases who will be raising awareness and giving talks.

We are honoured to be sponsoring such a large and celebrated event in the rare disease calendar and have no doubt it will be a great success.

Please click here for the programme, address and other details.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more